ClinicalTrials.gg
CompletedNCT05380635Updated Jun 7, 2023Results posted

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

A Phase 2 interventional study of Hypericin in Cutaneous T-Cell Lymphoma/Mycosis Fungoides, sponsored by Soligenix. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-07.

Sponsored by Soligenix · Phase 2, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 360 studies in Mycosis Fungoides with a site in United States — 24 open to participants now, 36 under way, none of them phase 3. Mycosis Fungoides · United States.

Enrollment
225th of 279
9 · median 32
Started
2022
with 5 others
Phase 2
101 of 360
8 open now
Registered
339th of 360
by date

Among the 360 studies in Mycosis Fungoides with a site in United States, this one is the 225th largest by enrollment of the 279 interventional ones that give a count, is one of 6 that started in 2022, is one of 101 in phase 2, and was the 339th registered.

Mycosis Fungoides

447 studies on the registry are indexed under Mycosis Fungoides; 42 are open to participants now.

Browse Mycosis Fungoides studies →

Open to participants now

24 of the 360 studies in Mycosis Fungoides with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Mycosis Fungoides studies recruiting now, 25 (83%) set no upper age limit and 1 (3%) stops at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 360 studies in Mycosis Fungoides with a site in United States, or all of them as a file.
02

Study summary

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

03

Conditions studied

  • Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Browse trials for

Keywords

  • CTCL
  • MF
  • Hypericin
  • HyBryte
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A clinical diagnosis of cutaneous T-cell lymphoma (CTCL, mycosis fungoides), Stage IB or Stage IIA
  • CTCL lesions covering ≥ 10% of their body surface area

Exclusion criteria

Exclusion Criteria:

  • History of allergy or to any of the components of HyBryte
  • Pregnancy or mothers who are breast-feeding
  • Males and females not willing to use effective
  • Subjects with history of sun hypersensitivity or photosensitive dermatoses (e.g., porphyria, systemic lupus erythematosus (SLE), Sjogren's syndrome, etc.)
  • Subjects whose condition is spontaneously improving
  • Subjects receiving topical or other topical treatments (e.g., nitrogen mustard) on index lesions for CTCL within 2 weeks of enrollment
  • Subjects receiving systemic steroids, psoralen ultraviolet A (UVA) radiation therapy (PUVA), narrow band ultraviolet B (UVB) light therapy (NB-UVB) or carmustine (BCNU) or other systemic therapies for CTCL within 3 weeks of enrollment
  • Subjects who have received electron beam irradiation within 3 months of enrollment
  • Subjects with a history of significant systemic
  • Subjects taking other drugs or drugs of abuse within 30 days of enrollment
  • Subjects receiving drugs known to cause photosensitization within 2 weeks of starting HyBryte therapy unless they have not had evidence of photosensitization after receiving a stable dose of the medication for a minimum of 4 weeks
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    HyBryte (0.25 % Hypericin)

    HyBryte (0.25 % hypericin) ointment will be applied to CTCL lesions and treated with visible light 18-24 hours later starting at 5 J/cm\^2. Drug application/light session will be done twice a week (at least 2 calendar days apart) for 8 weeks.

    Drug: Hypericin

Interventions

  • HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment.

    Also known as: HyBryte, SGX301

06

What researchers measure

Primary outcomes

  1. Electrocardiograms (ECG)

    Assess any ECG QT interval changes (defined as any occurrences of QT interval \>500 ms or changes in QT interval \>60 ms) during standard HyBryte photodynamic therapy.

    Time frame: 10 weeks

  2. Systemic Blood Levels

    Assess the systemic blood levels of hypericin during standard HyBryte photodynamic therapy.

    Time frame: 10 weeks

Secondary outcomes

  1. Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

    A treatment response was defined as a ≥50% improvement in CAILS score at Week 10 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.

    Time frame: 10 weeks

  2. Number of Index Lesions With a Treatment Response as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

    A treatment response was defined as a ≥50% improvement in CAILS score at Week 10 when compared to the CAILS score at baseline in each of the individual Index Lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

    Time frame: 10 weeks

  3. Number of Index Lesions With a Complete Response as Defined as a 100% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

    A complete response was defined as a 100% improvement in CAILS score (a CAILS score of 0) at Week 10 in each of the individual Index Lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

    Time frame: 10 weeks

07

Results

Posted Jun 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneHyBryte (0.25 % Hypericin)
Started9
Completed9
Not completed0

Outcome measures

PrimaryElectrocardiograms (ECG)

Assess any ECG QT interval changes (defined as any occurrences of QT interval \>500 ms or changes in QT interval \>60 ms) during standard HyBryte photodynamic therapy.

Time frame:
10 weeks
Reported as:
Count of participants · Participants
Electrocardiograms (ECG)
ParticipantsHyBryte (0.25 % Hypericin)
Electrocardiograms (ECG)0
PrimarySystemic Blood Levels

Assess the systemic blood levels of hypericin during standard HyBryte photodynamic therapy.

Time frame:
10 weeks
Reported as:
Mean · ug/mL
Systemic Blood Levels
ug/mLHyBryte (0.25 % Hypericin)
Systemic Blood Levels0.00013 ± 0.00011
SecondaryNumber of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

A treatment response was defined as a ≥50% improvement in CAILS score at Week 10 when compared to the CAILS score at baseline. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome. The overall CAILS score was calculated by adding the total score as described above for each of the 3 lesions. The overall CAILS score has a range of 0 to 111. A lower score means a better outcome.

Time frame:
10 weeks
Reported as:
Count of participants · Participants
Number of Responders and Non-Responders With a Treatment Response in 3 Treated Lesions as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.
ParticipantsHyBryte (0.25 % Hypericin)
Responder2
Non-Responder7
SecondaryNumber of Index Lesions With a Treatment Response as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

A treatment response was defined as a ≥50% improvement in CAILS score at Week 10 when compared to the CAILS score at baseline in each of the individual Index Lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

Time frame:
10 weeks
Reported as:
Count of units · Index Lesions
Number of Index Lesions With a Treatment Response as Defined as a ≥50% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.
Index LesionsHyBryte (0.25 % Hypericin)
Responder7
Non-Responder20
SecondaryNumber of Index Lesions With a Complete Response as Defined as a 100% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.

A complete response was defined as a 100% improvement in CAILS score (a CAILS score of 0) at Week 10 in each of the individual Index Lesions. The Composite Assessment of Index Lesion Disease Severity (CAILS) score measures: Erythema (or redness) on a scale of 0 (no redness) to 8 (very red), Scaling on a scale of 0 (no scaling) to 8 (all of the lesion is covered by a very rough surface), Plaque Elevation on a scale of 0 (no evidence of plaque above normal skin level) to 3 (plaque shows marked elevation above normal skin level) and Surface Area on a scale of 0 (no lesion/surface area is 0 cm\^2) to 18 (the lesion is larger than 300 cm\^2). A lower score means a better outcome.

Time frame:
10 weeks
Reported as:
Count of units · Index Lesions
Number of Index Lesions With a Complete Response as Defined as a 100% Improvement in the Composite Assessment of Index Lesion Disease Severity (CAILS) Score.
Index LesionsHyBryte (0.25 % Hypericin)
Responder4
Non-Responder23

Adverse events

Collected over 10 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
HyBryte (0.25 % Hypericin)0/9 (0%)0/9 (0%)3/9 (33.3%)
Most frequent other events
Most frequent other events
EventHyBryte (0.25 % Hypericin)
PruritisSkin and subcutaneous tissue disorders1/9
UrticariaSkin and subcutaneous tissue disorders1/9
Photosensitivity reactionSkin and subcutaneous tissue disorders1/9
Coronavirus infectionInfections and infestations1/9
Skin infectionInfections and infestations1/9
ChillsGeneral disorders1/9

Baseline characteristics

Age, Continuous
Age, Continuous(years)HyBryte (0.25 % Hypericin)
Mean62.0 ± 7.79
Sex: Female, Male
Sex: Female, Male(Participants)HyBryte (0.25 % Hypericin)
Female4
Male5
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)HyBryte (0.25 % Hypericin)
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)HyBryte (0.25 % Hypericin)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Rochester Skin Lymphoma Medical Group
    Fairport, New York 14450, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2022 to primary completion in Aug 2022, 3 months.

Results were first posted in Jun 2023, 9 months after primary completion.

Of 42 phase 2 interventional studies under Mycosis Fungoides, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 111. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 19, 2022
StartActual
May 9, 2022
Primary completionActual
Aug 16, 2022
CompletionActual
Aug 16, 2022
Results first posted
Jun 7, 2023
Last update
Jun 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05380635
Lead sponsor
Soligenix
Responsible party
Sponsor
First posted
May 19, 2022
Start date
May 9, 2022
Primary completion
Aug 16, 2022
Completion
Aug 16, 2022
Results posted
Jun 7, 2023
Last update
Jun 7, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hypericin

Start the discussion